Cidara Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Cidara Therapeutics

16/05/2024 23:54

* Cidara Therapeutics Inc  CDTX.OQ  reported a quarterly
adjusted
loss of $2.28​​ per share for the quarter ended in March, lower
than the same quarter last year, when the company reported EPS
of 60 cents.  The mean expectation of three analysts for the
quarter was for a loss of 20 cents per share. 
    * Revenue fell 67.4% to $8.46 million from a year ago;
analysts
expected $6.30 million. 
    * Cidara Therapeutics Inc's reported EPS for the quarter was
a
loss of $2.28​.
    * The company reported a quarterly loss of $10.33 million.
    * Cidara Therapeutics Inc shares had fallen by 30.9% this
quarter and lost 20.0% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 84.6%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Cidara
Therapeutics Inc is $40.00 
This summary was machine generated from LSEG data May 16 at
10:53 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.20          -2.28          Missed
 Dec. 31 2023      -2.07          -0.80          Beat
 Sep. 30 2023      -3.25          -1.80          Beat
 Jun. 30 2023      -2.60          -2.80          Missed